Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,874 shares of the medical equipment provider's stock after selling 4,226 shares during the period. Clark Estates Inc. NY owned approximately 0.05% of Lantheus worth $3,120,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after buying an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC bought a new position in shares of Lantheus during the third quarter worth about $1,066,000. Massachusetts Financial Services Co. MA bought a new position in shares of Lantheus during the third quarter worth about $25,955,000. Van ECK Associates Corp lifted its position in shares of Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock worth $6,469,000 after purchasing an additional 21,604 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded up $6.11 during trading hours on Friday, hitting $106.34. The stock had a trading volume of 1,369,851 shares, compared to its average volume of 921,738. The stock's fifty day simple moving average is $90.43 and its 200 day simple moving average is $96.80. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The firm has a market capitalization of $7.28 billion, a price-to-earnings ratio of 17.69 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. JMP Securities reissued a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus price target of $132.86.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.